Literature DB >> 27094200

Pharmacogenetics of Clopidogrel: An Unresolved Issue.

Naveen L Pereira1, Jeffrey B Geske2, Manuel Mayr2, Svati H Shah2, Charanjit S Rihal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27094200     DOI： 10.1161/CIRCGENETICS.115.001318

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN： 1942-3268


× No keyword cloud information.
  8 in total

1.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

2.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

3.  Genetic screening to avoid adverse drug reactions from medication use and approach patients' better outcomes: A lesson learn from the report of the Queen Savang Vadhana Memorial Hospital.

Authors:  Kessada Tunwongsa; Malinee Chonnawakul; Nopavut Geratikornsupuk; Karunrat Tewthanom
Journal:  Health Sci Rep       Date:  2022-04-13

Review 4.  An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.

Authors:  Antony Martin; Jennifer Downing; Michelle Maden; Nigel Fleeman; Ana Alfirevic; Alan Haycox; Munir Pirmohamed
Journal:  Pharmacogenomics       Date:  2017-11-02       Impact factor: 2.533

5.  Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.

Authors:  Urszula Adamiak-Giera; Anna Czerkawska; Szymon Olędzki; Mateusz Kurzawski; Krzysztof Safranow; Maria Jastrzębska; Barbara Gawrońska-Szklarz
Journal:  Pharmacol Rep       Date:  2020-12-03       Impact factor: 3.024

6.  A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy.

Authors:  Mariana Angulo-Aguado; Karen Panche; Caroll Andrea Tamayo-Agudelo; Daniel-Armando Ruiz-Torres; Santiago Sambracos-Parrado; Maria Jose Niño-Orrego; Nathaly Páez; Laura B Piñeros-Hernandez; Luisa-Fernanda Castillo-León; Juan Mauricio Pardo-Oviedo; Katherine Parra Abaunza; Paul Laissue; Nora Contreras; Carlos Alberto Calderón-Ospina; Dora Janeth Fonseca-Mendoza
Journal:  J Pers Med       Date:  2021-05-12

7.  Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Authors:  Joel A Morales-Rosado; Kashish Goel; Lingxin Zhang; Axel Åkerblom; Saurabh Baheti; John L Black; Niclas Eriksson; Lars Wallentin; Stefan James; Robert F Storey; Shaun G Goodman; Gregory D Jenkins; Bruce W Eckloff; Suzette J Bielinski; Hugues Sicotte; Stephen Johnson; Veronique L Roger; Liewei Wang; Richard Weinshilboum; Eric W Klee; Charanjit S Rihal; Naveen L Pereira
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.947

Review 8.  Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.

Authors:  Sherry-Ann Brown; Naveen Pereira
Journal:  J Pers Med       Date:  2018-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.